Molecular Genetics and Markers of Progression

[1]  D. Tindall,et al.  Isolation and androgen regulation of the human homeobox cDNA, NKX3.1 , 1998, The Prostate.

[2]  A. Hagemeijer,et al.  Cytogenetic analysis of 39 prostate carcinomas and evaluation of short-term tissue culture techniques. , 1998, Cancer genetics and cytogenetics.

[3]  T. Ried.  Interphase cytogenetics and its role in molecular diagnostics of solid tumors. , 1998, The American journal of pathology.

[4]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[5]  W. Isaacs,et al.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. , 1998, Cancer research.

[6]  K. Kinzler,et al.  14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .

[7]  K. Kinzler,et al.  The Genetic Basis of Human Cancer , 1997 .

[8]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[9]  E. Fearon.  Human cancer syndromes: clues to the origin and nature of cancer. , 1997, Science.

[10]  Gert Auer,et al.  Tumor cytogenetics revisited: comparative genomic hybridization and spectral karyotyping , 1997, Journal of Molecular Medicine.

[11]  M. Augustus,et al.  Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. , 1997, Cancer research.

[12]  R. deVere White,et al.  Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  O. Kallioniemi,et al.  Genome screening by comparative genomic hybridization. , 1997, Trends in genetics : TIG.

[14]  J. Melamed,et al.  Allelic loss on chromosome 13q in human prostate carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  S. Piantadosi,et al.  Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  J. Pannek,et al.  Prostate-specific antigen: what's new in 1997. , 1997, Oncology.

[17]  G. Raj,et al.  Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. , 1997, The Journal of urology.

[18]  M W Kattan,et al.  Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  C. Sheehan,et al.  HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. , 1997, Human pathology.

[20]  L. Chung,et al.  Metastasis induced by overexpression of p185neu‐T after orthotopic injection into a prostatic epithelial cell line (NbE) , 1997, Molecular carcinogenesis.

[21]  R. T. Curtis,et al.  A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. , 1997, Genomics.

[22]  J. Herman,et al.  Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer , 1997, Genes, chromosomes & cancer.

[23]  J. Ross,et al.  Prognostic significance of HER‐2/neu gene amplification status by fluorescence in Situ hybridization of prostate carcinoma , 1997, Cancer.

[24]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[25]  J. Moul,et al.  Inhibition of the growth of pre‐established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector , 1997, International journal of cancer.

[26]  M. Shen,et al.  Tissue‐specific expression of murine Nkx3.1 in the male urogenital system , 1997, Developmental dynamics : an official publication of the American Association of Anatomists.

[27]  A. Brothman.  Cytogenetic studies in prostate cancer: are we making progress? , 1997, Cancer genetics and cytogenetics.

[28]  R. Eisenman,et al.  Myc target genes. , 1997, Trends in biochemical sciences.

[29]  P. Kantoff,et al.  The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Thomas Ried,et al.  Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping , 1997, Nature Genetics.

[31]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[32]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[33]  W. Isaacs,et al.  Tumour-suppressor genes in prostatic oncogenesis: a positional approach. , 1997, British journal of urology.

[34]  J. Moul,et al.  Mutations of the p16 gene product are rare in prostate cancer , 1997, The Prostate.

[35]  Y. Arai,et al.  c‐erbB‐2 oncoprotein: A potential biomarker of advanced prostate cancer , 1997, The Prostate.

[36]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[37]  D. Bostwick,et al.  Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.

[38]  D. Slamon,et al.  HER‐2/neu Signal Transduction in Human Breast and Ovarian Cancer , 1997, Stem cells.

[39]  L. Chung,et al.  Androgen-repressed phenotype in human prostate cancer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B Kuska,et al.  Cancer genome anatomy project set for take-off. , 1996, Journal of the National Cancer Institute.

[41]  C. Bieberich,et al.  Prostate-specific and Androgen-dependent Expression of a Novel Homeobox Gene* , 1996, The Journal of Biological Chemistry.

[42]  J. Moul,et al.  The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? , 1996, Urology.

[43]  D. Bostwick,et al.  Absence of p16/MTS1 gene mutations in human prostate cancer. , 1996, Carcinogenesis.

[44]  D A Meyers,et al.  Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search , 1996, Science.

[45]  L. Liotta,et al.  Laser Capture Microdissection , 1996, Science.

[46]  Thomas Ried,et al.  Multicolour spectral karyotyping of mouse chromosomes , 1996, Nature Genetics.

[47]  W. Grizzle,et al.  Elevated serum levels of p105erbB‐2 in patients with advanced‐stage prostatic adenocarcinoma , 1996, International journal of cancer.

[48]  C. Harris,et al.  Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. , 1996, Journal of the National Cancer Institute.

[49]  R. Becker,et al.  Enumeration of interphase chromosomes. Comparison of visual in situ hybridization and confocal fluorescence in situ hybridization. , 1996, Analytical and quantitative cytology and histology.

[50]  F. Mostofi,et al.  Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. , 1996, The Journal of urology.

[51]  D. Schaid,et al.  Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. , 1996, Cancer research.

[52]  F. Hamdy,et al.  bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. , 1996, British Journal of Cancer.

[53]  W. Isaacs,et al.  Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. , 1996, Cancer research.

[54]  K. Cooney,et al.  Identification and characterization of proximal 6q deletions in prostate cancer. , 1996, Cancer research.

[55]  D. Johnston,et al.  Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. , 1996, Human gene therapy.

[56]  J. Yokota,et al.  Point Mutations of the Mxil Gene are Rare in Prostate Cancers , 1996, The Prostate.

[57]  K. Akakura,et al.  Codon 877 Mutation in the Androgen Receptor Gene in Advanced Prostate Cancer: Relation to Antiandrogen Withdrawal Syndrome , 1996, The Prostate.

[58]  R. Weinberg,et al.  How cancer arises. , 1996, Scientific American.

[59]  J. Brooks,et al.  An uncertain role for p53 gene alterations in human prostate cancers. , 1996, Cancer research.

[60]  F. Mostofi,et al.  Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. , 1996, Surgery.

[61]  D. Bostwick,et al.  Molecular biology of prostatic intraepithelial neoplasia , 1996, The Prostate.

[62]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.

[63]  P. Carroll,et al.  Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. , 1996, Cancer research.

[64]  J. Schalken,et al.  p16 mutations/deletions are not frequent events in prostate cancer. , 1996, British Journal of Cancer.

[65]  H. Klocker,et al.  Regulation of prostatic growth and function by peptide growth factors , 1996, The Prostate.

[66]  D. Samid,et al.  Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. , 1996, Molecular pharmacology.

[67]  L. Liotta,et al.  Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. , 1996, Cancer research.

[68]  K. Kawabe,et al.  Histochemical detection of intranuclear DNA fragmentation and its relation to the expression of bcl-2 oncoprotein in human prostatic cancer. , 1996, British Journal of Urology.

[69]  John Calvin Reed,et al.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.

[70]  P. Tamboli,et al.  Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. , 1996, Urology.

[71]  J. Moul,et al.  Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. , 1996, The Journal of urology.

[72]  A. Brothman,et al.  Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer. , 1996, The Journal of urology.

[73]  P. Scardino,et al.  Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  W. Symmans,et al.  Transfected neu oncogene induces human prostate cancer metastasis , 1996, The Prostate.

[75]  G. Buchanan,et al.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  Franck Bladou,et al.  Prostatic cell lineage markers: Emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration , 1996, International journal of cancer.

[77]  M. Skolnick,et al.  CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. , 1995, Oncogene.

[78]  J. Moul,et al.  Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. , 1995, Urology.

[79]  T. Shuin,et al.  Retinoblastoma gene mutations in primary human prostate cancer , 1995, The Prostate.

[80]  D. Grignon,et al.  Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. , 1995, Cancer research.

[81]  S. Elledge,et al.  In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. , 1995, Cancer research.

[82]  J. Weissenbach,et al.  Loss of the chromosomal region 10q23-25 in prostate cancer. , 1995, Cancer research.

[83]  J. Moul,et al.  p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[84]  O. Cussenot,et al.  Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[85]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[86]  A. Passaniti,et al.  Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. , 1995, Cancer research.

[87]  Kathleen R. Cho,et al.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.

[88]  H. Perlman,et al.  Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. , 1995, Cancer research.

[89]  M. Oshimura,et al.  Localization of metastasis suppressor gene(s) for rat prostatic cancer to the long arm of human chromosome 10 , 1995, Genes, chromosomes & cancer.

[90]  D. Bostwick,et al.  Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. , 1995, Cancer research.

[91]  J. Moul,et al.  Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. , 1995, The Journal of urology.

[92]  Z. Su,et al.  Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[93]  L. Liotta,et al.  Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. , 1995, Cancer research.

[94]  Hiroyoshi Suzuki,et al.  Mutational Analysis of CDKN2 (CDK4I/MTS1) Gene in Tissues and Cell Lines of Human Prostate Cancer , 1995, Japanese journal of cancer research : Gann.

[95]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[96]  J. Barrett,et al.  KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. , 1995, Science.

[97]  G. Coetzee,et al.  The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. , 1995, Cancer research.

[98]  L. Donehower,et al.  Androgen suppressed apoptosis is modified in p53 deficient mice. , 1995, Oncogene.

[99]  David G. Bostwick,et al.  High grade prostatic intraepithelial neoplasia. The most likely precursor of prostate cancer , 1995 .

[100]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[101]  L Pinsky,et al.  Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. , 1995, Human molecular genetics.

[102]  D. Grignon,et al.  Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. , 1995, Cancer research.

[103]  Arthur R. Brothman,et al.  Mutation of the MXI1 gene in prostate cancer , 1995, Nature Genetics.

[104]  T. Visakorpi,et al.  Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. , 1995, Cancer research.

[105]  J. Brooks,et al.  Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas , 1995, The Prostate.

[106]  L. Hartwell,et al.  Cell cycle control and cancer. , 1994, Science.

[107]  P. Troncoso,et al.  Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. , 1994, Cancer research.

[108]  J. Neoptolemos,et al.  Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. , 1994, British Journal of Cancer.

[109]  F. Bosman,et al.  Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. , 1994, Cancer research.

[110]  J. Oesterling,et al.  The clinical usefulness of prostate specific antigen: update 1994. , 1994, The Journal of urology.

[111]  R. Bookstein,et al.  Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer , 1994, Genes, chromosomes & cancer.

[112]  O. Cussenot,et al.  Genetic alterations in localized prostate cancer: Identification of a common region of deletion on chromosome arm 18q , 1994, Genes, chromosomes & cancer.

[113]  H. Huland,et al.  Immunohistochemical detection of p53 protein in human prostatic cancer. , 1994, The Journal of urology.

[114]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[115]  T. Visakorpi,et al.  Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. , 1994, The American journal of pathology.

[116]  N. Chamberlain,et al.  The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. , 1994, Nucleic acids research.

[117]  M. Ittmann,et al.  Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. , 1994, The American journal of pathology.

[118]  G. Stemmermann,et al.  International comparison on ras gene mutations in latent prostate carcinoma , 1994, International journal of cancer.

[119]  D. Bostwick,et al.  Loss of chromosome arm 8p loci in prostate cancer: Mapping by quantitative allelic imbalance , 1994, Genes, chromosomes & cancer.

[120]  R. deVere White,et al.  p53 in prostate cancer: frequent expressed transition mutations. , 1994, Journal of the National Cancer Institute.

[121]  D. Grignon,et al.  Allelic loss in locally metastatic, multisampled prostate cancer. , 1994, Cancer research.

[122]  J. Moul,et al.  Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.

[123]  S. Fosså,et al.  Prostatic carcinoma: a multivariate analysis of prognostic factors. , 1994, British Journal of Cancer.

[124]  Y. Nakamura,et al.  Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8. , 1994, Cancer research.

[125]  S. Brewster,et al.  Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor gene loci in human prostatic carcinoma. , 1994, The Journal of urology.

[126]  M. Colombel,et al.  Enhanced expression of p53 mRNA and protein in the regressing rat ventral prostate gland. , 1994, Biochemical and biophysical research communications.

[127]  K. Fischbeck,et al.  Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer. , 1994, Biochemical and biophysical research communications.

[128]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[129]  N. Sato,et al.  Androgen receptor gene mutations in human prostate cancer , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[130]  W. Grizzle,et al.  Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[131]  J. Moul,et al.  Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. , 1993, The Journal of urology.

[132]  M. Hollstein,et al.  Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.

[133]  T. Jacks,et al.  Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[134]  P. Walsh,et al.  Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. , 1993, Cancer research.

[135]  D. Chopin,et al.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. , 1993, The American journal of pathology.

[136]  S. Hilsenbeck,et al.  p53 is mutated in a subset of advanced-stage prostate cancers. , 1993, Cancer research.

[137]  R. Sadasivan,et al.  Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. , 1993, The Journal of urology.

[138]  Dale McLerran,et al.  An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. , 1993, JAMA.

[139]  J H Wasson,et al.  A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. , 1993, Archives of family medicine.

[140]  R. Sadasivan,et al.  p53 expression in incidental prostatic cancer. , 1993, The American journal of the medical sciences.

[141]  H. Kastendieck,et al.  Cytogenetic survey of 32 cancers of the prostate. , 1993, Cancer genetics and cytogenetics.

[142]  T. Stamey,et al.  Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. , 1993, The Journal of clinical endocrinology and metabolism.

[143]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[144]  T. Visakorpi,et al.  Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[145]  T. Visakorpi,et al.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.

[146]  J. Ward,et al.  K‐ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men , 1992, Cancer.

[147]  A. Sandberg.  Chromosomal abnormalities and related events in prostate cancer. , 1992, Human pathology.

[148]  L. Jin,et al.  Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. , 1992, Genomics.

[149]  D. Neal,et al.  p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. , 1992, The Journal of urology.

[150]  F. Mitelman,et al.  Cytogenetic analysis of 57 primary prostatic adenocarcinomas , 1992, Genes, chromosomes & cancer.

[151]  K. Fischbeck,et al.  Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy , 1991, Nature.

[152]  U. Bergerheim,et al.  Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma , 1991, Genes, chromosomes & cancer.

[153]  R. deVere White,et al.  Activated ras alleles in human carcinoma of the prostate are rare. , 1991, Cancer research.

[154]  S. Maygarden,et al.  Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. , 1991, Human pathology.

[155]  E. Gelmann,et al.  v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. , 1991, Molecular endocrinology.

[156]  W. Isaacs,et al.  Allelic loss of chromosomes 16q and 10q in human prostate cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[157]  W. Isaacs,et al.  ras gene mutations in human prostate cancer. , 1990, Cancer research.

[158]  W. Lee,et al.  Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[159]  S. Piantadosi,et al.  Clinical evidence for and implications of the multistep development of prostate cancer. , 1990, The Journal of urology.

[160]  W. Lee,et al.  Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. , 1990, Science.

[161]  M. Benson,et al.  Gene activity during the early phase of androgen-stimulated rat prostate regrowth. , 1989, Cancer research.

[162]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[163]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[164]  M. Greene,et al.  The neu (c-erbB-2) oncogene. , 1989, Seminars in oncology.

[165]  J. Southgate,et al.  Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ , 1989, Cell.

[166]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[167]  J. Yokota,et al.  AMPLIFICATION OF c-erbB-2 ONCOGENE IN HUMAN ADENOCARCINOMAS IN VIVO , 1986, The Lancet.

[168]  K. Semba,et al.  A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[169]  C R King,et al.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.

[170]  R. Weinberg,et al.  Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts , 1981, Nature.

[171]  M. Oshimura,et al.  Isochromosome 17 in prostatic cancer. , 1975, The Journal of urology.

[172]  H. Third.  Hæmolytic Disease of the New-Born , 1958, Nature.

[173]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[174]  L. Shaffer,et al.  Spectral karyotyping refines cytogenetic diagnostics of constitutional chromosomal abnormalities , 1997, Human Genetics.

[175]  S. Sell,et al.  Human Cytogenetic Cancer Markers , 1997, Contemporary Biomedicine.

[176]  William D. Foulkes,et al.  The CDKN2A (p16) Gene and Human Cancer , 1997, Molecular medicine.

[177]  J. Bruix,et al.  Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. , 1997, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[178]  A. Mundy,et al.  The source of urinary nitrosamines in patients with enterocystoplasties. , 1997, British journal of urology.

[179]  Chung Lee,et al.  Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells , 1996 .

[180]  P. Wingo,et al.  Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.

[181]  P. Carroll,et al.  Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). , 1995, The Journal of urology.

[182]  J. Rhim,et al.  Neoplastic transformation of a human prostate epithelial cell line by the v‐Ki‐ras oncogene , 1993, The Prostate.

[183]  C. Poremba,et al.  [Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer]. , 1993, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[184]  T. Visakorpi,et al.  New prognostic factors in prostatic carcinoma. , 1993, European urology.

[185]  F. Hofstädter.  Grading of prostate carcinoma , 1993 .

[186]  R. Sadasivan,et al.  Mutant p53 expression in prostate carcinoma , 1993, The Prostate.

[187]  A. Sandberg.  Cytogenetic and molecular genetic aspects of human prostate cancer: primary and metastatic. , 1992, Advances in experimental medicine and biology.

[188]  G. Miller,et al.  Expression of c‐erb B‐2/neu proto‐oncogene in human prostatic cancer tissues and cell lines , 1992, Molecular carcinogenesis.

[189]  J. Karr,et al.  Prostate Cancer and Bone Metastasis , 1992, Advances in Experimental Medicine and Biology.

[190]  J W Moul,et al.  Infrequent RAS oncogene mutations in human prostate cancer , 1992, The Prostate.

[191]  F. S. French,et al.  Expression of ras proto‐oncogenes in the dunning R3327 rat prostatic adenocarcinoma system , 1988, The Prostate.

[192]  K. Semba.  A v-erbB-related protooncogene, c-erb-B-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma , 1985 .

[193]  F. Mostofi,et al.  Grading of prostatic carcinoma. , 1975, Cancer chemotherapy reports.